These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 13671079)

  • 1. [Effect of a dose of tumor tissue antigens on specific antibody formation].
    FILATOV PP
    Biull Eksp Biol Med; 1959 Jun; 47(6):95-100. PubMed ID: 13671079
    [No Abstract]   [Full Text] [Related]  

  • 2. [The suitability of the Schultz-Dale reaction for the demonstration of specific tumor antigens. A critical comment].
    WITTIG G; TEICHMANN B; SCHNEEWEISS U
    Acta Biol Med Ger; 1962; 8():274-89. PubMed ID: 14007782
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives of host-tumor relationships. Preface and introduction.
    Weiss DW
    Isr J Med Sci; 1971 Jan; 7(1):1-6. PubMed ID: 5545763
    [No Abstract]   [Full Text] [Related]  

  • 4. [Relation of antitumor antibody titer to the nature of antigenic stimulus].
    LOMAKIN MS
    Biull Eksp Biol Med; 1958 Sep; 46(9):92-6. PubMed ID: 13607539
    [No Abstract]   [Full Text] [Related]  

  • 5. Antigen arrays for antibody profiling.
    Robinson WH
    Curr Opin Chem Biol; 2006 Feb; 10(1):67-72. PubMed ID: 16406767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Contemporary molecular-biological methods of cancer diagnosis and monitoring based on the humoral immune response to tumor-associated antigens].
    Shebzukhov IuV; Belousov PV; Khlgatian SV; Sazykin AIu; Kuprash DV; Nedospasov SA
    Mol Gen Mikrobiol Virusol; 2007; (2):3-6. PubMed ID: 17600920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Further observations on the cytotoxic action of serum from patients with malignant neoplasms].
    Pitzurra M; Jorio A; Costabile F
    Boll Soc Ital Biol Sper; 1966 Feb; 42(3):125-7. PubMed ID: 5945192
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohematologic aspects of cancer of clinical significance.
    Davidsohn I
    Tex Med; 1965 Sep; 61(9):662-6. PubMed ID: 5318337
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification and validation of cell surface antigens for antibody targeting in oncology.
    Carter P; Smith L; Ryan M
    Endocr Relat Cancer; 2004 Dec; 11(4):659-87. PubMed ID: 15613445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of antibody production in response to antigens of normal and tumor-bearing rabbit tissues in rats with developed tolerance].
    RADZIKHOVSKAIA RM
    Vopr Onkol; 1962; 8(11)():8-10. PubMed ID: 13990395
    [No Abstract]   [Full Text] [Related]  

  • 12. [Evolution and selection of the cancer cell].
    Flückiger P
    Med Welt; 1966 Oct; 42():2261-4. PubMed ID: 5978476
    [No Abstract]   [Full Text] [Related]  

  • 13. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
    Peggs KS; Quezada SA; Korman AJ; Allison JP
    Curr Opin Immunol; 2006 Apr; 18(2):206-13. PubMed ID: 16464564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
    Jinushi M; Hodi FS; Dranoff G
    Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Studies on the antibody (precipitin) content of the cornea after the simultaneous administration of different antigens; contribution to the problem of local antibody formation in the cornea].
    SCHWAB F
    Albrecht Von Graefes Arch Ophthalmol; 1959; 160(6):592-627. PubMed ID: 13661033
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple paths to multispecificity.
    Mariuzza RA
    Immunity; 2006 Apr; 24(4):359-61. PubMed ID: 16618592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.
    Reimer TA; Anagnostopoulos I; Erdmann B; Lehmann I; Stein H; Daniel P; Dörken B; Rehm A
    BMC Cancer; 2005 May; 5():47. PubMed ID: 15904507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Some methods for the demonstration of antigen-antibody reactions using antigens dissolved in colloidal dispersions].
    KLEINE N; MULLER W; MATTHES M
    Z Immun exp ther; 1958 May; 115(5):380-90. PubMed ID: 13581900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.